Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery

par van Veelen, M L C, Avezaat, C, Kros, J, van Putten, W, Vecht, C.
Publié 1998

The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients.

par Vecht, C J, Avezaat, C J, van Putten, W L, Eijkenboom, W M, Stefanko, S Z
Publié 1990

Heterogeneous X inactivation in trophoblastic cells of human full-term female placentas.

par Looijenga, L H, Gillis, A J, Verkerk, A J, van Putten, W L, Oosterhuis, J W
Publié 1999

Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer.

par van der Gaast, A., van Putten, W. L., Oosterom, R., Cozijnsen, M., Hoekstra, R., Splinter, T. A.
Publié 1991

Response to adjuvant chemotherapy in primary breast cancer: no correlation with expression of glutathione S-transferases.

par Peters, W. H., Roelofs, H. M., van Putten, W. L., Jansen, J. B., Klijn, J. G., Foekens, J. A.
Publié 1993

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.

par Foekens, J. A., Portengen, H., Look, M. P., van Putten, W. L., Thirion, B., Bontenbal, M., Klijn, J. G.
Publié 1994

Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients.

par Romain, S., Chinot, O., Klijn, J. G., van Putten, W. L., Guirou, O., Look, M., Martin, P. M., Foekens, J. A.
Publié 1994

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.

par Hilkens, P. H., Pronk, L. C., Verweij, J., Vecht, C. J., van Putten, W. L., van den Bent, M. J.
Publié 1997

Immediate and intermediate results of stent therapy for aortic coarctation

par Honing-Hemmers, A.M., van Putten, W.K., Gewillig, M., Mast, G., Talsma, M., Tanke, R., de Wolff, D., Sreeram, N.
Publié 2003

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

par van der Burg, M E L, de Wit, R, van Putten, W L J, Logmans, A, Kruit, W H J, Stoter, G, Verweij, J
Publié 2002

Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cance...

par Bontenbal, M., Foekens, J. A., Lamberts, S. W., de Jong, F. H., van Putten, W. L., Braun, H. J., Burghouts, J. T., van der Linden, G. H., Klijn, J. G.
Publié 1998

Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients

par de Witte, J H, Sweep, C G J, Klijn, J G M, Grebenschikov, N, Peters, H A, Look, M P, van Tienoven, Th H, Heuvel, J J T M, van Putten, W L J, Benraad, Th J, Foekens, J A
Publié 1999

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

par Wortman, B. G., Creutzberg, C. L., Putter, H., Jürgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. H. W., van der Steen-Banasik, E. M., Mens, J. W. M., Slot, A., Kroese, M. C. Stenfert, van Triest, B., Nijman, H. W., Stelloo, E., Bosse, T., de Boer, S. M., van Putten, W. L. J., Smit, V. T. H. B. M, Nout, R. A.
Publié dans Br J Cancer (2018)